Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival

Journal of Bone and Mineral Research

Volumn 18, Issue 3, 2003, Pages 482-492

  Croucher, Peter I ^a   De Raeve, Hendrik ^b   Perry, Mark J ^c   Hijzen, Anja ^d   Shipman, Claire M ^a   Lippitt, Jennifer ^e   Green, Jonathan ^f   Van Marck, Eric ^b   Van Camp, Ben ^d   Vanderkerken, Karin ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonate; Lytic lesion; Multiple myeloma; Osteoclast; Zoledronic acid

Indexed keywords

PARAPROTEIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY BURDEN; BONE DENSITY; BONE DISEASE; BONE MINERAL; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; RAT STRAIN; TREATMENT OUTCOME;

ANIMALS; BONE DENSITY; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; IMIDAZOLES; MICE; MICE, INBRED C57BL; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0242308942     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.3.482     Document Type: Article

References (51)

1. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME 1982 Quantitative histology of myeloma-induced bone changes. Br J Haematol 52:601-610.
2. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C 1991 Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62-66.
3. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA 1992 Abnormal bone remodelling in patients with myelomatosis and normal biochemical indicies of bone resorption. Eur J Haematol 49:192-198.
4. Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Gougados M, Amor B 1994 Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:41-49.
5. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Landsdorp PM, di Guglielmo R 1989 Production of interleukin 1 by bone marrow myeloma cells. Blood 74:380-387.
6. Kawano M, Yamamoto I, Iwato K, Tanaka H, Asaoku H, Tanabe O, Ishikawa H, Nobuyoshi M, Ohmoto Y, Hirai Y, Kuramoto A 1989 Interleukin-1beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma. Blood 73:1646-1649.
7. Yamamoto I, Kawano M, Sone T, Iwato K, Tanaka H, Ishikawa H, Kitamura N, Lee K, Shigeno C, Konishi J, Asaoku H, Tanabe O, Nobuyoshi M, Ohmoto Y, Hirai Y, Higuchi M, Ohsawa T, Kuramoto A 1989 Production of interleukin-1β, a potent bone resorbing cytokine, by human myeloma cells. Br J Haematol 49:4242-4246.
8. Garrett IR, Durie BGM, Nedwin GE, Gillespie A, Bringman T, Sabatini M, Bertolini DR, Mundy GR 1987 Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Eng J Med 317:526-532.
9. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M 2000 Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96:671-675.
10. Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A 1996 Hepatocyte growth factor and its receptor c-Met in multiple myeloma. Blood 88:3998-4004.
11. Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A 1996 Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines. J Biol Chem 271:24655-24661.
12. 1-VCAM-1 interaction. Bone 23:S180.
13. Oyajobi BO, Garrett IR, Williams PJ, Yoneda T, Anderson DM, Mundy GR 2000 A soluble murine receptor activator of NF-kB- human immunoglobulin fusion protein (RANK. Fc) inhibits bone resorption in a murine model of human multiple myeloma bone disease. J Bone Miner Res 15:S176.
14. Shipman CM, Holen I, Lippitt JM, Vandenberghe E, Croucher PI 2000 Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 96:360a.
15. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJR, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540.
16. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S 2001 Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow micro-environment. Blood 98:3527-3533.
17. Pearce RN, Sordillo EM, Yaccoby S, Wong BR. Liau DF, Colman N, Michaeli J, Epstein J, Choi Y 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581-11586.
18. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomma I 1992 Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340:1049-1052.
19. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA 1998 A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100:317-325.
20. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Black stock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med 334:488-493.
21. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J. Kandra A 1998 Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: A double-blind placebo-controlled trial. Br J Haematol 101:280-286.
22. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1998 Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 16:593-602.
23. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT 2001 Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 113:1035-1043.
24. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PI 1997 Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity. Br J Haematol 98:665-672.
25. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL, Bataille R 1999 Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14:2048-2056.
26. Tassone P, Forciniti S, Galea E, Morrone G, Turco M, Martinelli V, Tagliaferri P, Venuta S 2000 Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14:841-844.
27. Kunzmann V, Bauer E, Wilhelm M 1999 Gamma/delta T-cell stimulation by pamidronate. N Eng J Med 340:737-738.
28. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M 2000 Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:298-304.
29. Das H, Wang L, Kamath A, Bukowski JF 2001 Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98:1616-1618.
30. Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, Radl J, Mundy GR 1999 Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 93:1697-1706.
31. Cruz JC, Alsina M, Craig F, Yoneda T, Anderson JL, Dallas M, Roodman GD 2001 Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 29:441-447.
32. Radl J, De Glopper E, Schuit HR, Zurcher C 1979 Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice. J Immunol 122:609-613.
33. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, Thielemans K, Van Camp B 1997 Organ involvement and phenotypic adhesion profile of 5T2 and 5T33MM cells in the C57BL/KaLwRij mouse. Br J Cancer 76:451-460.
34. Asosingh K, Radl J, Van Riet I, Van Camp B, Vanderkerken K 2000 The 5TMM series: A useful in vivo mouse model of human multiple myeloma. Hematol J 1:351-356.
35. Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B 1996 Follow-up of bone lesions in an experimental multiple myeloma mouse model: Description of an in vivo technique using radiography dedicated for mammography. Br J Cancer 73:1463-1465.
36. Green JR, Muller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751.
37. Radl J, Croese JW, Zurcher C, VanDen Enden Hyphenvieveen MH, de Leeuw AM 1988 Animal model of human disease: Multiple myeloma. Am J Pathol 132:177-181.
38. Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B 1999 Insulin like growth factor-1 acts as a chemoattractant for 5T2 multiple myeloma cells. Blood 93:235-241.
39. Rosen LS, Gordon D, Antonio BS, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Tfrin M. Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y 2001 Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double blind, comparative trial. Cancer J 7:377-387.
40. Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Van Camp B, Russell RGG, Croucher PI 2000 The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established myeloma. Br J Haematol 111:283-286.
41. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
42. Van Valckenborgh E, De Raeve H, Devy L, Blacher S, Munaut C, Noel A, Van Marck E, Van Riet I, Van Camp B, Vanderkerken K 2002 Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer 86:796-802.
43. Yaccoby S, Pearce RN, Johnson CL, Barlogie B, Choi Y, Epstein J 2002 Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278-290.
44. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T 1995 Bisphosphonate risedronate reduces metastatic breast cancer burden in bone in mice. Cancer Res 55:3551-3557.
45. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ 1998 Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589.
46. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138.
47. van Beek E, Pieterman E, Lowik C, Papapoulos S 1999 Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 14:108-111.
48. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ 2001 Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242.
49. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green J 2002 Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J Pharm Exp Ther 303:1055-1061.
50. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ 1998 The bisphosphonate Incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58:5294-5297.
51. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A 1998 In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12:220-229.